Anticipated benefits and surprising effects of daclizumab in multiple sclerosis
- PMID: 20163991
- DOI: 10.1016/S1474-4422(10)70032-6
Anticipated benefits and surprising effects of daclizumab in multiple sclerosis
Comment on
-
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Lancet Neurol. 2010. PMID: 20163990 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical